Saturday December 4th, 2021 8:48PM

BioNTech boss: Europe will reach herd immunity this summer

By The Associated Press
Related Articles
  Contact Editor

BERLIN (AP) — Europe can achieve herd immunity against the coronavirus within three to four months, the head of German pharmaceutical company BioNTech, which developed the first widely approved COVID-19 vaccine with U.S. partner Pfizer, said Wednesday.

While the exact threshold required to reach that critical level of immunization remains a matter of debate, experts say a level above 70% would significantly disrupt transmission of the coronavirus within a population.

“Europe will reach herd immunity in July, latest by August,” Ugur Sahin, BioNTech's chief executive, told reporters.

He cautioned that this herd immunity initially wouldn't include children, as the vaccine has so far only been approved for people over 16. A small number of children who fall ill with COVID-19 suffer serious illness or long-term effects.

BioNTech's vaccine makes up a large share of the doses administered in North America, where it is more commonly known as the Pfizer shot, and Europe, which has been seen vaccination rates rise after a slugging start.

Sahin said data from people who have received the vaccine show that the immune response gets weaker over time, and a third shot will likely be required.

Studies show the efficacy of the BioNTech-Pfizer vaccine declines from 95% to about 91% after six months, he said.

“Accordingly, we need a third shot to get the vaccine protection back up to almost 100% again” Sahin said.

Vaccine recipients currently receive a second dose three weeks after their first shot, although some countries have longer intervals. Sahin suggested the third should be administered nine to 12 months after the first shot.

“And then I expect it will probably be necessary to get another booster every year or perhaps every 18 months,” he said.

Concerns have been raised that existing vaccines might be less effective against new variants of the virus now emerging in different parts of the world.

Sahin said BioNTech has tested its vaccine against more than 30 variants, including the now-dominant one first detected in Britain, and found the shot triggers a good immune response against almost all of them in the lab. In cases where the immune response was weaker, it remained sufficient, he said, without providing exact figures.

Asked about the new variant first detected in India, Sahin said the vaccine's effectiveness against it was still being investigated.

“But the Indian variant has mutations that we have previously investigated and against which our vaccine also works, so I am confident there, too,” he said.

The Mainz-based company's work developing a vaccine based on messenger RNA, or mRNA, benefited from its earlier research into pharmaceuticals to treat cancer, as tumors often try to adapt to evade the immune system, Sahin said.

“The way our vaccine works is that it has two points of attack,” he explained. Along with stimulating the production of antibodies, it prompts the body's so-called T-cells to attack the virus, he said.

“The vaccine is quite cleverly constructed, and the bulwark will hold. I'm convinced of that," Sahin said. “If the bulwark needs to be strengthened again, we'll do so. I'm not worried.”

The company is investigating reports of heart inflammation cases in people who received the vaccine in Israel, but so far hasn't seen any data that would indicate a heightened risk, Sahin said. Some 5 million people in Israel have been vaccinated, primarily with the BioNTech/Pfizer shot, giving it one of the highest coverages in the world.

“We take everything we hear very seriously,” Sahin said. “The most important principle in drug development is to do no harm.”

BioNTech expects to receive approval in July for its vaccine to be used in China, where it cooperates with local firm Fosun Pharma, he said.

Meanwhile, BioNTech and Pfizer are working with other manufacturers to ramp up production of the mRNA shot as worldwide demand still far outstrips supply.

“When we started 2021, our goal was to produce 1.3 billion doses, and now we've increased that to 3 billion doses,” said Sahin, praising pharmaceutical giants such as Novartis, Sanofi and Baxter for joining in the effort.

His company is in talks to create production facilities in Asia, South America and Africa, and may also issue special licenses to other “really competent” manufacturers to boost global supply of the vaccine, Sahin said.

“We don't want to have a low-quality vaccine in Africa,” he added, dismissing suggestions that the recipe for it could simply be made freely available.

Countering fierce criticism that the European Union had bungled its vaccine procurement process, Sahin said the 27-nation bloc deserved praise for managing to coordinate the simultaneous delivery of the first batches to all member states at the end of December.

“Europeans can be proud that they found a fair solution,” he said, adding that the bloc also exported large numbers of doses elsewhere.

“It doesn't help if Europeans are safe and other countries, where the virus is still raging, keep churning out new variants,” he said.

Sahin founded BioNTech in 2008 with his wife, the scientist Ozlem Tureci. Together they decided to pivot from cancer research to developing a coronavirus vaccine in early 2020 and reached out to Pfizer, which had the necessary expertise to conduct large-scale clinical trials.

The 55-year-old, whose family emigrated from Turkey to Germany when he was 4, told members of Germany's foreign press association VAP that it was "a very nice feeling” to be hearing of more and more people who are able to finally see loved ones again after getting vaccinated with his company's shot.

Sahin said he expects a “new normal” soon, where “one can move about freely and most people have a very good immune protection” against the virus.

Even so, some people would either not want to get vaccinated or have a weak immune system “and we have to consider these people too,” he said.


Follow AP’s pandemic coverage at and

  • Associated Categories: Associated Press (AP), AP Health, AP Business, AP Business - Industries, AP Business - Health Care
© Copyright 2021
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
BioNTech boss: Europe will reach herd immunity this summer
The head of German pharmaceutical company BioNTech says Europe can achieve herd immunity against the coronavirus "in July, latest by August."
8:40AM ( 6 minutes ago )
Greek PM: Vaccine hesitancy driving high death rate
Greece’s prime minister has issued an appeal for elderly Greeks to get vaccinated, blaming hesitancy for persistently high rates of death and hospitalization
8:28AM ( 18 minutes ago )
Chicago stages drive-through Wagner in underground garage
A bit of Richard Wagner's “Ring” cycle is being performed in an underground parking garage in Chicago
8:27AM ( 18 minutes ago )
Associated Press (AP)
The Latest: Tokyo residents asked to stay home for holidays
Japanese officials are asking the people to stay home during a string of “golden week” holidays beginning Thursday in a nationwide effort to curb the rapid resurgence of coronavirus cases less than three months before the Tokyo Olympics
6:46AM ( 2 hours ago )
Chinese companies considers mixing vaccines, booster shots
Chinese vaccine makers are looking at mixing their jabs and whether a booster shot could help better protect against COVID-19
3:35AM ( 5 hours ago )
Facing $11B tax bill, Samsung heirs donate massive art trove
Samsung’s founding family says it will donate tens of thousands of rare artworks, including Picassos and Dalis, and give hundreds of millions of dollars to medical research to help them pay a massive inheritance tax following last year’s death of chairman Lee Kun-Hee
3:33AM ( 5 hours ago )
AP Health
Sony's profit zooms to record on video games, 'Demon Slayer'
Sony’s January-March profit zoomed eight-fold to 107 billion yen, or $982 million from a year earlier, as people stuck at home during the coronavirus pandemic turned to the Japanese electronics and entertainment company’s video games and other visual content
8:03AM ( 42 minutes ago )
Biden to pitch sweeping 'family plan' in speech to Congress
President Joe Biden will use his first joint address to Congress to pitch a $1.8 trillion investment in children, families and education that would transform the role government plays in American life
7:42AM ( 1 hour ago )
FBI starts probe into death of Black man killed by deputies
The FBI has launched a civil rights probe into the death of Andrew Brown Jr., a Black man killed by deputies in North Carolina
7:17AM ( 1 hour ago )
AP Business
Democrats move to reinstate methane rules loosened by Trump
Congressional Democrats are moving to reinstate regulations designed to limit potent greenhouse gas emissions from oil and gas fields
12:14AM ( 8 hours ago )
Asian shares mostly higher ahead of Fed meeting
Asian shares are mostly moderately higher in listless trading as investors watch for news out of a Federal Reserve meeting
11:51PM ( 8 hours ago )
Asian lender forecasts strong rebound for region in 2021
The Asian Development Bank forecasts that developing Asian economies will grow at a solid 7.3% pace this year after contracting slightly in 2020 due to the pandemic
10:32PM ( 10 hours ago )
AP Business - Industries
The Latest: CDC: Vaccinated can go outside without mask
U.S. health officials say fully vaccinated Americans don’t need to wear masks outdoors unless they are in a big crowd of strangers
12:30PM ( 20 hours ago )
The Latest: Merck in deal with India on antiviral drug
Merck announced a deal with five makers of generic drugs in India to produce molnupiravir, an experimental antiviral similar to the COVID-19 medicine remdesivir but in a more convenient pill form
11:01AM ( 21 hours ago )
The Latest: Minnesota child dies of COVID-19 complications
A young child from southwestern Minnesota has died of COVID-19 complications, according to the state Department of Health
8:19AM ( 1 day ago )
AP Business - Health Care
Greek PM: Vaccine hesitancy driving high death rate
Greece’s prime minister has issued an appeal for elderly Greeks to get vaccinated, blaming hesitancy for persistently high rates of death and hospitalization
8:28AM ( 18 minutes ago )
India grieves 200K dead, with likely many more uncounted
India’s official death toll has passed 200,000, but the true number is likely far higher
8:27AM ( 19 minutes ago )
Boeing posts $537 million loss in Q1, less than a year ago
Boeing is posting another loss as the pandemic continues to undercut demand for new planes and the company deals with more problems around its 737 Max jetliner
8:25AM ( 21 minutes ago )
8 people dead in building blaze in Latvian capital Riga
Official in Latvia say eight people, some of them foreign nationals, have died in a fire at a building that housed an illegal hostel in the center of Riga, the capital
8:23AM ( 23 minutes ago )
UK watchdog steps up probe into Johnson's apartment refurb
Britain’s political spending watchdog is scaling up an investigation into Prime Minister Boris Johnson’s finances
8:19AM ( 27 minutes ago )